Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA

Neurology

Volumn 66, Issue 3, 2006, Pages 313-318

  Ovbiagele, Bruce ^a,c   Hills, Nancy K ^b   Saver, Jeffrey L ^a   Johnston, S Claiborne ^b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; TRANSIENT ISCHEMIC ATTACK; AGE; CARDIOVASCULAR DISEASE; DRUG UTILIZATION; MIDDLE AGED; STATISTICS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; REGISTRIES;

EID: 33646202307     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000196476.10103.52     Document Type: Article

References (39)

1. Global population at a glance: 2002 and beyond. www.Census.Gov/prod/ 2004pubs/wp02-1.Pdf; last accessed on July 1, 2005.
2. Hazzard W, Ettinger WH. Aging and atherosclerosis: changing considerations in cardiovascular disease prevention as the barrier to immortality is approached in old age. Am J Geriatr Cardiol 1995;4:16-36.
3. Brown R, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
4. Marini C, Baldassarre M, Russo T, et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004;62:77-81.
5. Coull A, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: Implications for public education and organisation of services. Br Med J 2004;328: 326.
6. Public health and aging: hospitalizations for stroke among adults aged >/=65 years-United States, 2000. MMWR 2003;52:586-589.
7. Wolf P, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999;30:1991-1994.
8. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2004;35:1023.
9. Albers G, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483S-512S.
10. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient isch-aemic attack. Lancet 2001;358:1033-1041.
11. Munoz M, Marrugat J. [Secondary prevention of coronary heart disease is less aggressive in patients over 64 years]. Rev Esp Cardiol 2003;56:586-593.
12. Philippe F, Danchin N, Quentzel S, et al. [Utilization of the principal therapeutic classes for cardiovascular prevention in elderly patients seen by cardiologists. The Eliage Survey. Ann Cardiol Angeiol (Paris) 2004;53:339-346.
13. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003;55:604-608.
14. Strandberg T, Pitkala K, Kulp S, et al. Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population-based cross-sectional survey in helsinki, finland. Eur J Clin Pharmacol 2001;57:513-516.
15. Lawlor D, Whincup P, Emberson JR, et al. The challenge of secondary prevention for coronary heart disease in older patients: Findings from the British Women's Heart and Health Study and the British Regional Heart Study. Fam Pract 2004;21:582-586.
16. Williams M, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735-1743.
17. Quilliam B, Lapane KL. Clinical correlates and drug treatment of residents with stroke in long-term care. Stroke 2001;32:1385-1393.
18. Moroney J, Tseng CL, Paik MC, et al. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc 1999;47:824-829.
19. Volpato S, Maraldi C, Ble A, et al. Prescription of antithrombotic therapy in older patients hospitalized for transient ischemic attack and ischemic stroke: The GIFA Study. Stroke 2004;35:913-917.
20. Simpson C, Wilson C, Hannaford PC, et al. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 2005;36:1771-1775.
21. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64:654-659.
22. Kinsella K, Phillips DR. Global Aging: The challenge of success. Population bulletin - a publication of the population reference bureau, http:// www.Prb.Org/template.Cfm?Templat =interestdisplay.Cfm; last accessed July 29, 2005.
23. Manton K, Vaupel JW. Survival after the age of 80 in the United States, Sweden, France, England, and Japan. N Engl J Med 1995;333:1232-1235.
24. Campion E. The oldest old N Engl J Med 1994;330:1819-1820.
25. Kannisto A. Development of oldest-old mortality, 1950-1990: evidence from 28 developed countries. Odense, Denmark: Odense University Press, 1994.
26. Lloyd-Jones D, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294:466-472.
27. Chobanian A, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
28. Aronow H, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 2003;163:2576-2582.
29. Fonarow G. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med. 2003; 4(suppl 3): S37-S46.
30. Marti J, Anton E. Stroke in the very elderly. Stroke. 2005; 36: 705-706.
31. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-1703.
32. Kailani S, Wright JT. Hypertension in African Americans: evaluation and treatment issues. J Assoc Acad Minor Phys 1991;2:162-167.
33. Schmader K, Hanlon JT, Fillenbaum GG, et al. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing 1998;27:493-501.
34. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
35. Gore J, Goldberg RJ, Matsumoto AS, et al. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol 1984;54:722-725.
36. Kargman DE, Tuck C, Berglund L, et al. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis 1998;139:391-399.
37. Carlberg B, Asplund K, Hagg E. Factors influencing admission blood pressure levels in patients with acute stroke. Stroke 1991;22:527-530.
38. Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004;63:1217-1222.
39. Law M, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427.